SynthesisMovement disorders : official journal of the Movement Disorder Society2026
Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025.
Synthesis in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn the past decade, significant advances have improved our understanding of the mechanisms underlying HD pathobiology leading to several putative therapeutic targets for HD.
objectiveThe aim was to describe the Huntington's disease (HD) drug development clinical pipeline.
methodsWe analyzed all HD clinical trials described in clinicaltrials.gov and the WHO International Clinical Trials Registry from January 1, 2014, to November 13, 2025. Studies were classified as interventional (pharmacological and nonpharmacological) or observational (natural history, biomarker, and other). Interventional trials were further categorized according to phase of development and type of intervention. Proposed mechanisms of action were classified according to adapted Common Alzheimer's and Related Dementias Research Ontology definitions, with huntingtin lowering assigned as a separate category.
resultsA total of 165 registered clinical studies for Huntington's disease (HD) were identified between 2014 and the index date, requiring 7501 participants. These included 54 observational studies and 111 interventional trials. Of the 69 pharmacological trials, 54.9% have been completed, 10.8% have been terminated, and 39.2% remain active. Over the past 11 years, 50 different pharmacological agents have been tested in 69 trials, with 21 agents currently being evaluated. Disease-modifying therapies now account for 90.5% of phase 1 trials, 61.8% of phase 2 trials, and 55.6% of phase 3 trials in the pipeline.
conclusionsOver the past decade, the HD clinical trial landscape has expanded and shifted toward disease-modifying strategies, with significant changes in trial design and a shift in the target population to an earlier stage of disease. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.